Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)

被引：22
|
作者：
Chanan-Khan, A. [1 ]
Egyed, M. [2 ]
Robak, T. [3 ]
Martinelli de Oliveira, F. A. [4 ]
Echeveste, M. A. [5 ]
Dolan, S. [6 ]
Desjardins, P. [7 ]
Blonski, J. Z. [3 ]
Mei, J. [8 ]
Golany, N. [8 ]
Zhang, J. [8 ]
Gribben, J. G. [9 ]
机构：
[1] Mayo Clin, Div Hematol & Oncol, Jacksonville, FL 32224 USA
[2] Kaposi Mor Oktato Korhaz, Dept Internal Med, Kaposvar, Hungary
[3] Med Univ Lodz, Dept Hematol, Lodz, Poland
[4] Hosp Erasto Gaertner, Dept Oncol, Curitiba, Parana, Brazil
[5] Hosp Univ Donostia, Hematol Serv, San Sebastian, Spain
[6] St Johns Hosp, Div Hematol, St John, NB, Canada
[7] Hosp Charles LeMoyne, Dept Hematol, Greenfield Pk, PQ, Canada
[8] Celgene Corp, Summit, NJ USA
[9] Barts Canc Inst, Ctr Haemato Oncol, London, England
来源：
LEUKEMIA | 2017年 / 31卷 / 05期
关键词：
D O I：
10.1038/leu.2017.47
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1240 / 1243
页数：5
相关论文
共 50 条
  • [41] Cost-Effectiveness of Ibrutinib as First-line Treatment for Older Patients With Chronic Lymphocytic Leukemia in Iran
    Fariman, Soroush
    Nasab, Fatemeh Momeni
    Faraji, Hoda
    Afzali, Monireh
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 38 : 93 - 100
  • [42] Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison
    Suzy Van Sanden
    Simona Baculea
    Joris Diels
    Sarah Cote
    Advances in Therapy, 2017, 34 : 1650 - 1661
  • [43] Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
    Moreno, Carol
    Greil, Richard
    Demirkan, Fatih
    Tedeschi, Alessandra
    Anz, Bertrand
    Larratt, Loree
    Simkovic, Martin
    Samoilova, Olga
    Novak, Jan
    Ben-Yehuda, Dina
    Strugov, Vladimir
    Gill, Devinder
    Gribben, John G.
    Hsu, Emily
    Lih, Chih-Jian
    Zhou, Cathy
    Clow, Fong
    James, Danelle F.
    Styles, Lori
    Flinn, Ian W.
    LANCET ONCOLOGY, 2019, 20 (01): : 43 - 56
  • [44] AN ECONOMIC EVALUATION OF RITUXIMAB VERSUS OTHER FIRST-LINE TREATMENTS FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN POLAND
    Kawalec, P.
    Stawowczyk, E.
    Russel-Szymczyk, M.
    Szkultecka-Debek, M.
    Aultman, R.
    Carr, E.
    Lech-Maranda, E.
    Krawcewicz, A.
    Wach, M.
    Mazur, G.
    VALUE IN HEALTH, 2009, 12 (07) : A273 - A273
  • [45] Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis
    Kongnakorn, Thitima
    Sterchele, James A.
    Salvador, Christopher G.
    Getsios, Denis
    Mwamburi, Mkaya
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2014, 6 : 141 - 149
  • [46] Survival adjusting for crossover: phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma
    Coutre, Steven
    Tedeschi, Alessandra
    Robak, Tadeusz
    Barr, Paul M.
    Owen, Carolyn
    Bairey, Osnat
    Burger, Jan
    Zhou, Cathy
    Styles, Lori
    James, Danelle F.
    Kipps, Thomas J.
    HAEMATOLOGICA, 2018, 103 (06) : E249 - E251
  • [47] Combination Therapy with Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial
    Ferrajoli, Alessandra
    O'Brien, Susan
    Wierda, William G.
    Faderl, Stefan
    Badoux, Xavier
    Estrov, Zeev
    Schlette, Ellen
    Smith, Susan C.
    Ayala, Ana B.
    Falchi, Lorenzo
    Calin, Steliana
    Kantarjian, Hagop M.
    Keating, Michael J.
    BLOOD, 2011, 118 (21) : 780 - 780
  • [48] Optimizing First-Line Therapy for Patients With Chronic Myeloid Leukemia
    Fava, Carmen
    Cortes, Jorge
    SEMINARS IN HEMATOLOGY, 2009, 46 (02) : S5 - S10
  • [49] The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy
    Santacruz, Rodrigo
    Villamor, Neus
    Aymerich, Marta
    Martinez-Trillos, Alejandra
    Lopez, Cristina
    Navarro, Alba
    Rozman, Maria
    Bea, Silvia
    Royo, Cristina
    Cazorla, Maite
    Colomer, Dolors
    Gine, Eva
    Pinyol, Magda
    Puente, Xose S.
    Lopez-Otin, Carlos
    Campo, Elias
    Lopez-Guillermo, Armando
    Delgado, Julio
    HAEMATOLOGICA, 2014, 99 (05) : 873 - 880
  • [50] Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
    Badoux, Xavier C.
    Keating, Michael J.
    Wen, Sijin
    Wierda, William G.
    O'Brien, Susan M.
    Faderl, Stefan
    Sargent, Rachel
    Burger, Jan A.
    Ferrajoli, Alessandra
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (05) : 584 - 591
12345